ClearPoint Neuro, Inc., a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB, a global biopharmaceutical leader, to partner on drug delivery platforms for UCB’s gene therapy portfolio. Under the terms of the license agreement, UCB will utilize ClearPoint Neuro’s proprietary technology and services in connection with the development and commercialization of UCB’s gene therapy ...